faldoritinib   Click here for help

GtoPdb Ligand ID: 14628

Synonyms: Compound 204 [WO2023129667]
Compound class: Synthetic organic
Comment: Faldoritinib is the INN for a tyrosine kinase inhibitor that was included in WHO INN Proposed List 135 (July 2026). It is described as an antineoplastic agent. The structure is claimed in a number of patents for activity as a fms related receptor tyrosine kinase 3 (FLT3) inhibitor [3]. In the absence of a declared company code-to-structure, we predict that faldoritinib might be the INN for Biomea's orally bioavailable, covalent (irreversible) FLT3 inhibitor clinical lead BMF-500 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 3
Rotatable bonds 16
Topological polar surface area 135.73
Molecular weight 552.71
XLogP 1.06
No. Lipinski's rules broken 3

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC1=NC(=C(NC2=CC(=CC=C2)CCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C)N=C1N(C)C(C)C)C(=O)N
Isomeric SMILES N(C=1C(C(N)=O)=NC(CC)=C(N(C(C)C)C)N1)C2=CC(CCNC([C@@H](N(C(/C=C/CN(C)C)=O)C)C)=O)=CC=C2
InChI InChI=1S/C29H44N8O3/c1-9-23-28(36(7)19(2)3)34-27(25(33-23)26(30)39)32-22-13-10-12-21(18-22)15-16-31-29(40)20(4)37(8)24(38)14-11-17-35(5)6/h10-14,18-20H,9,15-17H2,1-8H3,(H2,30,39)(H,31,40)(H,32,34)/b14-11+/t20-/m0/s1
InChI Key BOKKFLKTQXTMQM-IXDOJHRFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Law B, Rughwani T, Archer TC, Kumar L, Lu D, Somanath P, Ma Y, Wang X, Sperandio D, Morris S, Kirschberg T et al.. (2022)
Bmf-500: An Orally Bioavailable Covalent Inhibitor of FLT3 with High Selectivity and Potent Antileukemic Activity in FLT3-Mutated AML.
Blood, 140 (Issue Supplement 1). DOI: 10.1182/blood-2022-170445
2. Lo Schiavo F, Salvesi C, Jandoubi M, Pirini F, Garbetta J, Martinelli G, Simonetti G, Ferrari A. (2025)
Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.
Mol Cancer, 24 (1): 266. [PMID:41126239]
3. Sperandio D, Butler T, Kirschberg TA, Wang X, Lin NH, Ungashe SB, Squires NH, Upasani RB, Phan T, Palmer JT et al.. (2023)
Pyrazine compounds as inhibitors of flt3.
Patent number: WO2023129667A1. Assignee: Biomea Fusion Inc. Priority date: 29/12/2022. Publication date: 06/07/2023.